Our first product and lead platform technology is AVERSA, and abuse deterrent tech which we believe to be applicable to any patch on the market today.
AVERSA™ Fentanyl Abuse Deterrent
Indication
AVERSA™ Transdermal Technology
Chronic Pain
Pre-Clinical
Phase 1
FDA Filing
AVERSA™ Buprenorphine Abuse Deterrent
Indication
AVERSA™ Transdermal Technology
Chronic Pain
Pre-Clinical
Phase 1
FDA Filing
AVERSA™ Methylphenidate
Indication
AVERSA™ Transdermal Technology
Attention Deficit Hyperactivity Disorder (ADHD)
Pre-Clinical
Phase 1
FDA Filing
4P Exenatide
Indication
Novel Transdermal
Type 2 Diabetes
Pre-Clinical
Phase 1
FDA Filing
4P FSH
Indication
Novel Transdermal
Infertility
Aversa™ abuse deterrent technology can be incorporated into any transdermal patch that has a risk of abuse.